Tony Pelz was a trader on a major European bank's proprietary trading desk, responsible for a portfolio with limits of more than $200 million. Prior to proprietary trading, Pelz worked with several global investment banks in roles ranging from corporate finance, M&A to credit and business development. He is author of The Biotech Trader Handbook, 2nd Edition, co-founder of the small-cap biotech research and trading site Chimera Research Group and operator of PelzOptions.com. Pelz currently resides in Denver, Colorado where he trades for his own account.
Recent Articles By The Author
Options Trade Into Ziopharm's Sarcoma Drug Study Results
Options expert Tony Pelz says options are the best way to trade Ziopharma's looming palifosamide data.
Dynavax Options Trade for Heplisav FDA Approval Decision
Options expert Tony Pelz offers investors a way to use options to trade Dynavax's upcoming FDA decision.
Alexza Pharma: Premium Selling Options Strategy
A new options trade for Alexza going into an FDA drug approval decision.
Amicus: Bullish Options Trade Into Clinical Trial Catalysts
Contributor Tony Pelz offers an options trade for those who believe Amicus shares are going higher.
Dynavax: Speculative Upside Options Trade
How to use options to play a possible run-up in Dynavax prior to the FDA's approval decision.
Exelixis: New Drug Approval Options Trade
Options wizard Tony Pelz suggests another way to trade Exelixis's FDA drug approval decision.
Eli Lilly: Bearish Options Trade
Tony Pelz offers a short-term options trade to take advantage of end-of-year selling in Eli Lilly.
Ziopharm: Options Trade for Phase III Data
How to play the high-risk release of results from Ziopharm's phase III study.
How to Hedge Profits in Sarepta Therapeutics
Options guru Tony Pelz offers options trades for those who want to protect their Sarepta profits.
NPS Pharma: Bullish Options Trade Into the Gattex FDA Panel
Biotech options expert Tony Pelz recommends a bullish options trade for the Oct. 16 Gattex FDA panel.